News
Company News: Allero Therapeutics and Abbreos Join Forces to Clinically Develop COVID-19 Program
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, and Abbreos Inc., a US- based IND-stage company focused on developing treatments that dampen hyperactive immune responses, today announced a clinical development agreement to treat medical conditions associated with potentially lethal amounts of pro-inflammatory cytokines and chemokines (“cytokine storm”). A first focus of the agreement is the treatment of patients likely to progress into COVID-19-associated acute respiratory distress syndrome (ARDS).
Company News: BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facility for Resorbable Medical Implants
– Seamless transition from R&D to commercial-scale additive manufacturing
– Leading-edge cleanroom, no-touch manufacturing
– GMP capabilities for internal and contract manufacturing
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Company News: Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
— First-in-class compound showed excellent tolerability and safety
— Unique mode of action in chronic heart failure confirmed by data on cardiac function and biomarkers
— Phase II studies in subacute and chronic heart failure planned
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today positive results of a Phase Ib study with its lead compound CDR132L. Read more…
Company News: Cardior Pharmaceuticals´ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model
— Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure
— Study by international research team published in European Heart Journal
— Broad treatment potential for chronic heart failure
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure. Read more…